Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

Article Figures & Data

Table 1

Contemporary multi-institutional reports—HD IL-2 outcome

Report	Response	Survival
Clark et al 4 RCC (2011–2015), sequenced with targeted therapy N=352 (328 with response data) PROCLAIM registry database	CR 4%, PR 13%, SD 39%, PD 43% CR+PR+SD 53%	Median OS—NR for CR, PR, SD Median OS—PD—15.5 months PD followed by TT—med OS 29.7 months; PD no TT—med OS 8.5 months 2.5-year OS—CR 100%; PR 75%, SD 78%, PD 39%
McDermott et al 5 RCC n=120 Multi-institution, prospective trial	ORR 25%, CR 3, PR 27 13 (11%) progression-free at 3 years	Median OS 42.8 months 80% TT after IL-2
Alva et al 6 mM (2005–2012)—n=170 RCC (2005–2012)—n=192 Survival current 2015 PROCLAIM registry database	mM: CR 5% PR 10% SD 22% CR+PR+SD 58% median f/u 43.1 months RCC: CR 6%, PR 9%, SD 22% CR+PR+SD 70% median f/u 46.6 months	Median OS 19.6 months Median OS—NR for CR, PR Median OS 33.4 months—SD Median OS 41 months Median OS—NR for CR, PR Median OS 49.6 months—SD
Stenehjem et al 7 RCC n=391 U Utah 1988–2013 U Mich 1997–2013	CR 9% PR 10%, SD 32% PD 42% CR+PR+SD 51%	Median OS CR—13+ years Median OS PR—37.8 months Median OS SD—34.4 months

CR, complete response; f/u, follow-up; IL, interleukin; mM, metastatic melanoma; N, number; NR, not reached; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; RCC, renal cell carcinoma; SD, stable disease; TT, targeted therapy; U, university.

Table 2

Patient outcomes and long-term toxicity (A) response and survival, (B) long-term toxicity

(A) Best response	Metastatic melanoma	Metastatic renal cell
(A) Best response	(n=54)	(n=46)
CR	43	38
Surgical/SRS CRs	9	5
PR No further treatment	2	3
Median follow-up	10+ years	10.5+ years
Range follow-up	5+ to 15+ years	5+ to 30+ years
Alive >10 years after IL-2 with no subsequent therapy	32 patients	27 patients

(B) Event	# Patients
Hypothyroidism—requiring replacement medication (grade 2)	5
Arthralgias/Arthritis (grade 1–2)	6
Vitiligo (grade 1–2)	3
Neuropathy (grade 2)	1
Premature ventricular contractions (grade 1)	1
Normal pressure hydrocephalus (grade 1)	1

CR, complete response; DFS, disease-free survival; IL-2, interleukin-2; PR, partial response; SRS, stereotactic radiosurgery.

Supplementary Data

This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Data supplement 1

Vol 69 Issue 4 Table of Contents